American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid and Useful for Clinicians Evaluating Obstructive CAD
28 sept. 2017 08h30 HE
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Sep 28, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today that in a Scientific Statement by the...
UPDATE - WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma
08 août 2017 13h19 HE
|
CDx Diagnostics
SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of...
WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma
08 août 2017 07h00 HE
|
CDx Diagnostics
SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of...
VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
05 juil. 2017 16h15 HE
|
VIVUS Inc.
CAMPBELL, CA--(Marketwired - Jul 5, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent...
New Study Published in The American Journal of Medicine Expands the Clinical Evidence Underscoring the Value of the Corus(R) CAD Blood Test to Help Safely Direct Cardiovascular Care
12 avr. 2017 08h00 HE
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Apr 12, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of results from the...
PROMISE Substudy Results, Published in the American Heart Journal, Provide Independent Validation of the Clinical Value of the Corus(R) CAD Blood Test to Accurately Identify Patients with Obstructive CAD
06 févr. 2017 08h00 HE
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Feb 6, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of a peer-reviewed substudy...
CardioDx Announces Final Endpoint Results from the PRESET Registry at the AHA Scientific Sessions 2016
14 nov. 2016 08h30 HE
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Nov 14, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from the final endpoint analysis...
Motif Bio Files Registration Statement for Proposed U.S. Public Offering of American Depositary Shares and Applies for NASDAQ Listing
13 juil. 2016 02h00 HE
|
Motif Bio
LONDON, UNITED KINGDOM--(Marketwired - Jul 13, 2016) - Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has...
Khush F. Mehta Joins CardioDx as Chief Executive Officer
01 juin 2016 08h30 HE
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Jun 1, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the appointment of Khush Mehta as President,...
New Data Demonstrate That WATS3D Is 4X More Effective Than the Seattle Random Biopsy Protocol in the Detection of High-Grade Dysplasia and Esophageal Adenocarcinoma
21 mai 2016 12h00 HE
|
CDx Diagnostics
SUFFERN, NY--(Marketwired - May 21, 2016) - CDx Diagnostics today announced final data from a multicenter, prospective, randomized, crossover study demonstrating a fourfold increase in the detection...